RGLS 4326

Drug Profile

RGLS 4326

Alternative Names: RGLS-4326

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autosomal dominant polycystic kidney disease

Most Recent Events

  • 05 Jul 2018 Regulus Therapeutics halts phase I multiple ascending dose (MAD) study due to unexpected observations in its 27-week mouse chronic toxicity study
  • 10 May 2018 Regulus Therapeutics plans a phase II proof-of-concept trial for Autosomal-dominant polycystic kidney disease in USA
  • 10 May 2018 Regulus Therapeutics initiates enrolment in a phase I MAD trial for Autosomal-dominant polycystic kidney disease (in healthy volunteers) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top